Abstract
What is known and objective: Neurotoxicity is a side effect of acyclovir. We report the first case, to our knowledge, whereby Bayesian-informed clearance estimates supported a therapeutic intervention for acyclovir-associated neurotoxicity. Case summary: A 62-year-old male with the diagnosis of disseminated zoster was being treated with intravenous (IV) acyclovir when he developed symptoms of acute neurotoxicity. Acyclovir had been dose-adjusted for renal dysfunction according to traditional creatinine clearance estimates; however, as the patient was also on vancomycin, Bayesian estimates of vancomycin clearances were performed, which revealed a 2-fold lower creatinine clearance. In response to the Bayesian estimates, acyclovir was discontinued, and improvements in mentation were noted within 24 hours. What is new and conclusion: Alternate approaches to estimate renal function beyond Cockcroft-Gault, such as a Bayesian approach used in our patient, should be considered when population estimates are likely to be inaccurate and potentially dangerous to the patient.
Original language | English (US) |
---|---|
Pages (from-to) | 350-355 |
Number of pages | 6 |
Journal | Journal of Clinical Pharmacy and Therapeutics |
Volume | 42 |
Issue number | 3 |
DOIs | |
State | Published - Jun 2017 |
Keywords
- acyclovir
- adverse effects
- pharmacodynamics
- pharmacokinetics
- statistical model
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)